{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:57:31Z","timestamp":1786982251393,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04421-6","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:22:09Z","timestamp":1781173329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of the CHAM score in non-small cell lung cancer patients treated with nivolumab"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5528-7852","authenticated-orcid":false,"given":"Ahmet Burak","family":"Agaoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9317-942X","authenticated-orcid":false,"given":"Ferhat","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-593X","authenticated-orcid":false,"given":"Mustafa","family":"Sahbazlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4859-7574","authenticated-orcid":false,"given":"Atike Pinar","family":"Erdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"1","key":"4421_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/biomedicines11010083","volume":"11","author":"M Maugeais","year":"2023","unstructured":"Maugeais M, P\u00e9ron J, Dalle S, Boespflug A, Duruissaux M, Corbaux P, et al. Impact of liver metastases and number of metastatic sites on immune-checkpoint inhibitors efficacy in patients with different solid tumors: a retrospective study. Biomedicines. 2023;11(1):83. https:\/\/doi.org\/10.3390\/biomedicines11010083.","journal-title":"Biomedicines"},{"issue":"5","key":"4421_CR2","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1080\/21645515.2020.1823779","volume":"17","author":"Y Huang","year":"2021","unstructured":"Huang Y, Zhu L, Guo T, Chen W, Zhang Z, Li W, et al. Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis. Hum Vaccin Immunother. 2021;17(5):1278\u201387. https:\/\/doi.org\/10.1080\/21645515.2020.1823779.","journal-title":"Hum Vaccin Immunother"},{"issue":"17","key":"4421_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174333","volume":"14","author":"M Xie","year":"2022","unstructured":"Xie M, Li N, Xu X, Xu Y, Li H, Zhu L, et al. The efficacy of PD-1\/PD-L1 inhibitors in patients with liver metastasis of non-small cell lung cancer: a real-world study. Cancers (Basel). 2022;14(17):4333. https:\/\/doi.org\/10.3390\/cancers14174333.","journal-title":"Cancers (Basel)"},{"key":"4421_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241511887","volume":"24","author":"K Tostes","year":"2023","unstructured":"Tostes K, Polo Siqueira A, Reis RM, Ferro Leal L, Arantes LMRB. Biomarkers for immune checkpoint inhibitor response in NSCLC: current developments and applicability. Int J Mol Sci. 2023;24:11887. https:\/\/doi.org\/10.3390\/ijms241511887.","journal-title":"Int J Mol Sci"},{"key":"4421_CR5","doi-asserted-by":"publisher","first-page":"15283","DOI":"10.2147\/JIR.S541842","volume":"18","author":"E Zeynelgil","year":"2025","unstructured":"Zeynelgil E, \u00c7a\u011flayan D, \u00c7elik S, Ayy\u0131ld\u0131z Sevim H, \u015eahinli H, Karakaya S,\u00a0et al. Do inflammatory and nutritional markers predict prognosis in metastatic non-small cell lung cancer patients receiving nivolumab. J Inflamm Res. 2025;18:15283\u201392. https:\/\/doi.org\/10.2147\/JIR.S541842.","journal-title":"J Inflamm Res"},{"issue":"2","key":"4421_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","volume":"19","author":"FG Dall\u2019Olio","year":"2022","unstructured":"Dall\u2019Olio FG, Marabelle A, Caramella C,\u00a0Garcia C, Aldea M, Chaput N,  et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2022;19(2):75\u201390. https:\/\/doi.org\/10.1038\/s41571-021-00564-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"4421_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193388","volume":"16","author":"T Ranjan","year":"2024","unstructured":"Ranjan T, Podder V, Margolin K, Velcheti V, Maharaj A, Ahluwalia MS. Immune checkpoint inhibitors in the management of brain metastases from non-small cell lung cancer: a comprehensive review of current trials, guidelines and future directions. Cancers (Basel). 2024;16:3388. https:\/\/doi.org\/10.3390\/cancers16193388.","journal-title":"Cancers (Basel)"},{"issue":"5 Suppl","key":"4421_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.26355\/eurrev_202310_34076","volume":"27","author":"S Menekse","year":"2023","unstructured":"Menekse S, Kut E, Almuradova E. Elevated serum lactate dehydrogenase to albumin ratio is a useful poor prognostic predictor of nivolumab in patients with non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2023;27(5 Suppl):86\u201394. https:\/\/doi.org\/10.26355\/eurrev_202310_34076.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"4421_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10147-019-01528-5","volume":"25","author":"K Suzuki","year":"2020","unstructured":"Suzuki K, Terakawa T, Furukawa J, Velcheti V, Maharaj A, Ahluwalia MS. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Int J Clin Oncol. 2020;25(1):135\u201344. https:\/\/doi.org\/10.1007\/s10147-019-01528-5.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"4421_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/14397595.2017.1366093","volume":"28","author":"S Fujimoto","year":"2018","unstructured":"Fujimoto S, Koga T, Kawakami A,\u00a0Kawabata H, Okamoto S, Mizuki M, et al. Tentative diagnostic criteria and disease severity classification for Castleman disease: a report of the research group on Castleman disease in Japan. Mod Rheumatol. 2018;28(1):161\u20137. https:\/\/doi.org\/10.1080\/14397595.2017.1366093.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"4421_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/bjh.18214","volume":"198","author":"DC Fajgenbaum","year":"2022","unstructured":"Fajgenbaum DC, Pierson SK, Kanhai K, Bagg A, Alapat D, Lim MS, et al. The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. Br J Haematol. 2022;198(2):307\u201316. https:\/\/doi.org\/10.1111\/bjh.18214.","journal-title":"Br J Haematol"},{"issue":"8","key":"4421_CR12","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1007\/s12094-017-1829-5","volume":"20","author":"J Garde-Noguera","year":"2018","unstructured":"Garde-Noguera J, Martin-Martorell P, De Juli\u00e1n M, Perez-Altozano J, Salvador-Coloma C, Garc\u00eda-Sanchez J, et al. Predictive and prognostic clinical and pathological factors of Nivolumab efficacy in non-small-cell lung cancer patients. Clin Transl Oncol. 2018;20(8):1072\u20139. https:\/\/doi.org\/10.1007\/s12094-017-1829-5.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"4421_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020203","volume":"8","author":"A Botticelli","year":"2020","unstructured":"Botticelli A, Cirillo A, Scagnoli S, Cerbelli B, Strigari L, Cortellini A, et al. The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy. Vaccines. 2020;8(2):203. https:\/\/doi.org\/10.3390\/vaccines8020203.","journal-title":"Vaccines"},{"key":"4421_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-019-0349-0","volume":"9","author":"C Zhang","year":"2019","unstructured":"Zhang C, Yu D. Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain? Cell Biosci. 2019;9:82. https:\/\/doi.org\/10.1186\/s13578-019-0349-0.","journal-title":"Cell Biosci"},{"key":"4421_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1039121","volume":"9","author":"DC Guven","year":"2022","unstructured":"Guven DC, Sahin TK, Erul E, Rizzo A, Ricci AD, Aksoy S, et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Mol Biosci. 2022;9:1039121. https:\/\/doi.org\/10.3389\/fmolb.2022.1039121.","journal-title":"Front Mol Biosci"},{"key":"4421_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02183","volume":"10","author":"RV Jimenez","year":"2019","unstructured":"Jimenez RV, Kuznetsova V, Connelly AN, Hel Z, Szalai AJ. C-reactive protein promotes the expansion of myeloid derived cells with suppressor functions. Front Immunol. 2019;10:2183. https:\/\/doi.org\/10.3389\/fimmu.2019.02183.","journal-title":"Front Immunol"},{"key":"4421_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.692142","volume":"11","author":"AER Kartikasari","year":"2021","unstructured":"Kartikasari AER, Huertas CS, Mitchell A, Plebanski M. Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. Front Oncol. 2021;11:692142. https:\/\/doi.org\/10.3389\/fonc.2021.692142.","journal-title":"Front Oncol"},{"key":"4421_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1725904","volume":"16","author":"EC Reed","year":"2026","unstructured":"Reed EC, Lauten TH, Natour T, Pitts LJ, Jojo CN, Griffin BL, et al. Hemoglobin alpha regulates T-lymphocyte activation and mitochondrial function. Front Immunol. 2026;16:1725904. https:\/\/doi.org\/10.3389\/fimmu.2025.1725904.","journal-title":"Front Immunol"},{"key":"4421_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920970049","volume":"12","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhang F, Yuan F, Li Y, Ma J, Ou Q, et al. Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Ther Adv Med Oncol. 2020;12:1758835920970049. https:\/\/doi.org\/10.1177\/1758835920970049.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"4421_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004342","volume":"10","author":"SH Tseng","year":"2022","unstructured":"Tseng SH, Cheng MA, Farmer E,\u00a0Ferrall L, Kung YJ, Lam B, et al. Albumin and interferon-\u03b2 fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity. J Immunother Cancer. 2022;10(4):e004342. https:\/\/doi.org\/10.1136\/jitc-2021-004342.","journal-title":"J Immunother Cancer"},{"key":"4421_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1549276","volume":"16","author":"S Shi","year":"2025","unstructured":"Shi S, Ou X, Liu C, Wen H, Ke J. Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment. Front Immunol. 2025;16:1549276. https:\/\/doi.org\/10.3389\/fimmu.2025.1549276.","journal-title":"Front Immunol"},{"issue":"4","key":"4421_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/diseases11040132","volume":"11","author":"DS Mouliou","year":"2023","unstructured":"Mouliou DS. C-reactive protein: pathophysiology, diagnosis, false test results and a novel diagnostic algorithm for clinicians. Diseases. 2023;11(4):132. https:\/\/doi.org\/10.3390\/diseases11040132.","journal-title":"Diseases"},{"issue":"5","key":"4421_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s12026-022-09299-4","volume":"70","author":"L Rao","year":"2022","unstructured":"Rao L, Zhang K, Luo H,\u00a0He S, Li Y, Liu C, et al. The ability of inflammatory markers to recognize infection in cancer patients with fever at admission. Immunol Res. 2022;70(5):667\u201377. https:\/\/doi.org\/10.1007\/s12026-022-09299-4.","journal-title":"Immunol Res"},{"issue":"10","key":"4421_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32100566","volume":"32","author":"N Kolk\u0131ran","year":"2025","unstructured":"Kolk\u0131ran N, Erdo\u011fan AP, \u015eahbazlar M, Ta\u015f S, G\u00f6k\u00f6z Do\u011fu G, Canaslan K, et al. SUVmax\u2013IPI as a new prognostic index in metastatic non-small cell lung cancer patients receiving nivolumab. Curr Oncol. 2025;32(10):566. https:\/\/doi.org\/10.3390\/curroncol32100566.","journal-title":"Curr Oncol"},{"key":"4421_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101835","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Rizzo A, Aksoy S, Guven DC. Prognostic significance of the Royal Marsden Hospital (RMH) score in patients with cancer: a systematic review and meta-analysis. Cancers (Basel). 2024;16:1835. https:\/\/doi.org\/10.3390\/cancers16101835.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"4421_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15072655","volume":"15","author":"E T\u00fcrkmen","year":"2026","unstructured":"T\u00fcrkmen E, Erdo\u011fan AP, \u015eahbazlar M, M\u00fctevelizade G, Ekinci F. Prognostic value of the SUVmax\u2013IPI composite score on overall survival in metastatic prostate cancer. J Clin Med. 2026;15(7):2655. https:\/\/doi.org\/10.3390\/jcm15072655.","journal-title":"J Clin Med"},{"issue":"1","key":"4421_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12967-019-1847-x","volume":"17","author":"A Botticelli","year":"2019","unstructured":"Botticelli A, Salati M, Di Pietro FR, Strigari L, Cerbelli B, Zizzari IG, et al. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. J Transl Med. 2019;17(1):99. https:\/\/doi.org\/10.1186\/s12967-019-1847-x.","journal-title":"J Transl Med"},{"issue":"2","key":"4421_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.30565\/medalanya.1314292","volume":"7","author":"OY Bal\u00e7\u0131k","year":"2023","unstructured":"Bal\u00e7\u0131k OY, Ayta\u00e7 A, Avc\u0131 T,\u00a0Demir B, \u0130lhan Y, Karakaya G, et al. Prognostic significance of PNI, SIRI and LIPI in non small-cell lung cancer. Acta Med Alanya. 2023;7(2):153\u201362. https:\/\/doi.org\/10.30565\/medalanya.1314292.","journal-title":"Acta Med Alanya"},{"issue":"4","key":"4421_CR29","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s10147-018-1250-2","volume":"23","author":"A Nakaya","year":"2018","unstructured":"Nakaya A, Kurata T, Yoshioka H, Takeyasu Y, Niki M, Kibata K, et al. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol. 2018;23(4):634\u201340. https:\/\/doi.org\/10.1007\/s10147-018-1250-2.","journal-title":"Int J Clin Oncol"},{"key":"4421_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611733","volume":"30","author":"LJ T\u00f3th","year":"2024","unstructured":"T\u00f3th LJ, Mok\u00e1nszki A, M\u00e9hes G. The rapidly changing field of predictive biomarkers of non-small cell lung cancer. Pathol Oncol Res. 2024;30:1611733. https:\/\/doi.org\/10.3389\/pore.2024.1611733.","journal-title":"Pathol Oncol Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04421-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04421-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04421-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:22:10Z","timestamp":1781173330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04421-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":30,"alternative-id":["4421"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04421-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Manisa Celal Bayar University (Decision No: E-20478486\u2013050.04\u2013968551, dated 05 March 2025) and was conducted by the Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Owing to the retrospective and anonymized nature of the study, informed consent for publication was not required in accordance with institutional and journal policies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}